Home›Stock Screener›Crop Life Science›Financial Statements

Crop Life Science Financial Statements

4 Years of Data
2026 - 2023

Crop Life Science financial statements. In FYNone, Crop Life Science (CLSL) reported revenue ₹0 Cr, net profit ₹0 Cr and EPS ₹0.00, with a net profit margin of 3.3% and ROE of 8.0%. Full financial statements from FY2023 to FY2026 (4 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Read Crop Life Science dividend payments for the complete payout history and dividend yield track record.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 3.35% 2026 data
EBITDA Margin 9.57% 2026 data
Operating Margin 9.00% 2026 data
Return on Assets 3.37% 2026 data
Return on Equity 7.95% 2026 data

Balance Sheet Ratios

Current Ratio 29.50 2026 data
Equity Ratio 42.31% 2026 data
Asset Turnover 1.00 2026 data

CLSL Revenue, Net Profit & EBITDA — Year-on-Year Growth

CLSL YoY (March 2026 vs Period) — revenue -100.0%, net profit -100.0%, EBITDA -100.0%, expenses -100.0%. For live price, earnings ratios and company overview, see Crop Life Science screener.

Revenue Growth
-100.0%
Year-over-Year
Net Profit Growth
-100.0%
Year-over-Year
EBITDA Growth
-100.0%
Year-over-Year
Expense Growth
-100.0%
Year-over-Year
Assets Growth
+14.3%
Year-over-Year
Equity Growth
+8.6%
Year-over-Year
Operating Cash Flow Growth
-300.0%
Year-over-Year
Investing Cash Flow Growth
+150.0%
Year-over-Year
Financing Cash Flow Growth
-28.6%
Year-over-Year

CLSL Income Statement — Revenue, EBITDA & Net Profit

Crop Life Science revenue ₹0 Cr, EBITDA ₹0 Cr, net profit ₹0 Cr, EPS ₹0.00 (None) — net profit margin 3.3%. Analyse CLSL institutional holdings to track promoter, FII and institutional holdings.

Periods ₹ Crores
Particulars None March 2026 March 2025 March 2024 March 2023
Revenue 0 209 202 201 132
Expenses 0 189 184 186 120
EBITDA 0 20 17 15 13
Operating Profit Margin % 0.00% 9.00% 8.00% 6.00% 9.00%
Depreciation 0 5 5 3 4
Interest 0 5 5 3 3
Profit Before Tax 0 9 8 8 6
Tax 0 3 2 2 2
Net Profit 0 7 6 6 4
Earnings Per Share (₹) 0.00 3.79 3.27 3.54 3.39

CLSL Balance Sheet — Assets, Liabilities & Shareholders' Equity

CLSL total assets ₹208 Cr, total equity ₹88 Cr, total liabilities ₹ Cr (2026) — ROE 8.0%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024 2023
ASSETS
Total Assets 208 182 180 102
Current Assets 177 142 140 86
Fixed Assets 30 38 39 16
Capital Work in Progress 0 0 0 0
Investments 1 1 0 0
Other Assets 177 143 141 86
LIABILITIES
Total Liabilities
Current Liabilities 6 8 11 6
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 88 81 76 41
Share Capital 17 17 17 12
Reserves & Surplus 67 60 55 29

CLSL Cash Flow Statement — Operating, Investing & Financing

Crop Life Science operating cash flow ₹-8 Cr, investing ₹2 Cr, financing ₹-9 Cr, net cash flow ₹-15 Cr (2026).

Periods ₹ Crores
Particulars March 2026 March 2025 March 2024 March 2023
Operating Activities -8 -2 -8 2
Investing Activities 2 -4 -3 -5
Financing Activities -9 -7 13 1
Net Cash Flow -15 -12 2 -2